JAC Advance Access published online on September 20, 2002
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkf190
© 2002 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In Brief
1 Department of Medical
Microbiology, Royal Free and University College Medical School,
London NW3 2PF, UK
* Corresponding author. E-mail: j.hamilton-miller{at}rfc.ucl.ac.uk.
Received 14 March 2002
; revised 2 May 2002
; accepted 31 July 2002
Objective: We have sought ways to
circumvent resistance, by combining nisin with other antibiotics
known to target bacterial cell wall biosynthesis. Methods: Twenty strains each of methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci
(VRE) were tested in vitro by standardized methods
against nisin alone and combined with bacitracin, ramoplanin and
chloramphenicol. Results: Ramoplanin was the most potent compound,
and bacitracin had the least activity. Two-way synergy was observed
with nisin and ramoplanin. However, chloramphenicol was clearly antagonistic
to the activity of nisin. Conclusions: Observations of synergy between
nisin and ramoplanin against MRSA and VRE offer a promising approach
to the concept of combining nisin with inhibitors of cell wall peptidoglycan.
Further investigations are needed in order to develop this approach
as a clinical possibility.
Nisin, alone and combined with peptidoglycan-modulating
antibiotics: activity against methicillin-resistant Staphylococcus
aureus and vancomycin-resistant enterococci
2 Department
of Microbiology, New York University School of Medicine, New York,
NY, USA
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Piper, L. A. Draper, P. D. Cotter, R. P. Ross, and C. Hill A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species J. Antimicrob. Chemother., September 1, 2009; 64(3): 546 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Millette, G. Cornut, C. Dupont, F. Shareck, D. Archambault, and M. Lacroix Capacity of Human Nisin- and Pediocin-Producing Lactic Acid Bacteria To Reduce Intestinal Colonization by Vancomycin-Resistant Enterococci Appl. Envir. Microbiol., April 1, 2008; 74(7): 1997 - 2003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jenssen, P. Hamill, and R. E. W. Hancock Peptide Antimicrobial Agents Clin. Microbiol. Rev., July 1, 2006; 19(3): 491 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Cotter, L. A. Draper, E. M. Lawton, O. McAuliffe, C. Hill, and R. P. Ross Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147. Appl. Envir. Microbiol., June 1, 2006; 72(6): 4492 - 4496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Drider, G. Fimland, Y. Hechard, L. M. McMullen, and H. Prevost The Continuing Story of Class IIa Bacteriocins Microbiol. Mol. Biol. Rev., June 1, 2006; 70(2): 564 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Higgins, R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt Jr., et al. Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1127 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Oliva, A. J. O'Neill, K. Miller, W. Stubbings, and I. Chopra Anti-staphylococcal activity and mode of action of clofazimine J. Antimicrob. Chemother., March 1, 2004; 53(3): 435 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ingham, M. Ford, R. J. Moore, and M. Tizard The bacteriocin piscicolin 126 retains antilisterial activity in vivo J. Antimicrob. Chemother., June 1, 2003; 51(6): 1365 - 1371. [Abstract] [Full Text] [PDF]
|
|